FUTURE OF HEALTHCARE

ClareMedica Health Partners, a Leading Provider of Value-Based Primary Care, Receives Investment from Revelstoke Capital Partners

Revelstoke | February 25, 2022

Revelstoke Capital Partners ("Revelstoke"), a Denver-based private equity firm focused on investing in healthcare services companies, today announced it has made a significant growth investment in ClareMedica Health Partners, LLC ("ClareMedica" or the "Company"), a leader in value-based primary care serving Medicare Advantage members in Florida. This partnership will accelerate ClareMedica's growth and aid the Company in expanding its BetterCare model into new markets.

ClareMedica will continue to be led by CEO Roberto Palenzuela and the current management team, who will retain significant ownership in the business. BPOC, a Chicago-based healthcare investor, which has been an investor in ClareMedica since 2019, will also retain equity ownership.

"We have always believed in a value-based care model that places a priority on high-quality coordinated care designed to improve health outcomes," said Mr. Palenzuela, who reinvested alongside Revelstoke. "We are delighted to partner with Revelstoke, which has a proven track-record of building prominent healthcare services businesses with this patient centric philosophy. We are excited to use this investment to partner with other physician-led practices, expanding our BetterCare model into new markets throughout Florida and into neighboring states."

Russell Cassella, Managing Partner at Revelstoke, said, "Our investment in ClareMedica reflects Revelstoke's avid support of the industry's transition from fee-for-service to value-based healthcare, resulting in a greater emphasis on improving patient outcomes. ClareMedica's commitment to providing high-quality care has made it a partner of choice for physicians and payors throughout Florida. With our experience in physician practice management and value-based care, we look forward to helping management build a broader regional platform that will increase access to high-quality care."

"We look forward to our continued partnership with Roberto and his team because of their patient-centered approach and focus on improving patient outcomes. As value-based care continues to expand, we see significant long-term growth potential as ClareMedica enters new markets and expands access to high-quality care."

Peter Magas, Partner at BPOC

"After a multi-year outbound search in the value-based primary care sector, we are very pleased to partner with ClareMedica's management team and providers who are dedicated to transforming healthcare," said Cy Barton-Dobenin, Principal at Revelstoke. "Throughout our targeted search process, we have built significant industry knowledge and strategic relationships that we are excited to integrate into ClareMedica's growth plans."

SVB Leerink acted as financial advisor and McGuireWoods LLP acted as legal counsel to Revelstoke. Houlihan Lokey acted as financial advisor and Kirkland & Ellis LLP and McDermott Will & Emery LLP acted as legal counsel to ClareMedica and BPOC. Terms of the transaction were not disclosed.

About Revelstoke

Revelstoke is a private equity firm formed by experienced investors who focus on building industry-leading companies in the healthcare services and healthcare technology sectors. Revelstoke partners with entrepreneurs and management teams to execute on a disciplined organic and acquisition growth strategy as it strives to build exceptional companies. Revelstoke is based in Denver, Colorado and has approximately $4.3 billion of assets under management. Since the firm's inception in 2013, Revelstoke has completed 142 acquisitions, which includes 25 platform companies and 117 add-on acquisitions. 

About ClareMedica Health Partners

ClareMedica is a growing health care company that provides and coordinates comprehensive health care services for Medicare Advantage members and other customers through a network of employed and affiliated physicians. We deliver accountable, value-based care for all health care stakeholders by employing a patient-centric care model that provides better care for our patients and a changing health care industry. 

About BPOC

Founded in 1996, BPOC is a Chicago-based private equity firm that invests exclusively in healthcare companies and is one of the nation's most experienced investors in the industry having raised five funds with total capital commitments of nearly $1.8 billion. BPOC has invested in numerous provider, manufacturing, outsourcing, distribution and information technology companies through growth equity, management buyouts and leveraged recapitalizations. 

Spotlight

Science and technology are paving the way for transformational advances in human health. At Johnson & Johnson Innovation, we recognize that a good idea can come from anywhere, and we work with partners at all stages of research and development to nurture the innovation ecosystem and propel the best ideas into solutions for patients.

Spotlight

Science and technology are paving the way for transformational advances in human health. At Johnson & Johnson Innovation, we recognize that a good idea can come from anywhere, and we work with partners at all stages of research and development to nurture the innovation ecosystem and propel the best ideas into solutions for patients.

Related News

HEALTH TECHNOLOGY

Medical Device Innovation Consortium Launches Initiative to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics

MDIC | August 23, 2022

The Medical Device Innovation Consortium formally launched its Somatic Reference Samples Initiative with a pilot project to improve the validation and regulatory review process for cancer diagnostics based on next generation sequencing. MDIC will lead a collaboration with the U.S. Food and Drug Administration the National Institute of Standards and Technology, National Institutes of Health and industry stakeholders to manufacture, validate, and distribute SRSs to simplify and support validation of NGS-based cancer diagnostics. The initiative also includes the goal to create a publicly available global genomic data resource library of datasets with the potential to be used by sponsors and regulators. “NGS is a powerful technology enabling breakthroughs in diagnostics and ultimately therapeutics. These diagnostic tests need to be validated for accurate clinical use, and reference samples are essential to the validation process. But well-characterized and widely accepted reference materials do not exist for NGS-based diagnostics, complicating the development and validation process. Through the MDIC SRS Initiative, we are developing reference samples and data sets that can be used globally by test developers and regulators to bring more consistency to NGS-based cancer diagnostic development, increasing the confidence and accuracy of these tests, which will ultimately lead to more accuracy in diagnosis and treatment for patients.” Andrew Fish, President and CEO, MDIC “There is a need for appropriately consented, highly characterized, and broadly available reference materials that may improve the accuracy, reliability, and transparency of NGS-based oncology tests and support the generation of validation data for use in regulatory submissions. The reference samples and datasets being created by the MDIC Somatic Reference Samples Initiative can help fulfill this need,” said Wendy Rubinstein, MD, PhD, Director, Personalized Medicine, Center for Devices and Radiological Health, U.S. Food and Drug Administration. Horizon Discovery, a PerkinElmer company, is conducting the development and manufacture of these reference samples. The goal of this pilot project is to individually engineer 10 gene variants clinically associated with cancer into a highly characterized human cell line – GM24385 using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology resulting in ten edited human cell lines, each containing one gene variant clinically associated with one or more specific cancers. The cell lines, containing confirmed sequences, will be combined and available in FFPE format. The fully characterized reference samples will be commercially available to the end users from Horizon and the characterization data will be accessible through public databases, including precisionFDA, an FDA-sponsored site for data information, sequencing, and bioinformatics. NIST’s involvement in this work is to foster understanding.* “As our collaboration validates the MDIC SRS samples, we will also learn and build best practices to improve the efficiency and sustainability of reference sample validation and dataset generation in general. This project is a major step in the development and optimization of new sequencing technologies and the translation of DNA sequencing to clinical applications for diagnosing and treating cancer,” said Justin Zook, PhD, Co-Leader, Biomarker and Genomic Sciences Group, National Institute of Standards and Technology. MDIC’s SRS project began as a working group in 2018, representing more than forty stakeholders with a mission to address the gap in reference material for NGS-based diagnostic tests. The initial output of this working group, MDIC’s SRS Landscape Analysis, published in 2019, was a comprehensive catalog of existing clinically relevant cancer variants and available reference samples. Based on the unmet needs discovered through the SRS Landscape Analysis, the SRS Initiative has prioritized a subset of ten variants to be engineered into reference samples for the pilot project. In addition to the utility of these samples in development, validation, and regulatory review, these samples potentially have value in reimbursement decisions, post-market monitoring and informing the path forward for addition SRS. The work in the SRS Initiative is funded in part by the Gordon and Betty Moore Foundation the National Philanthropic Trust, Illumina, and Quidel. Affiliation with a commercial product does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment identified are necessarily the best available for the purpose. About MDIC Founded in 2012, the Medical Device Innovation Consortium is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to transform health care into human care. Collaborating with our partners to advance science, we enable transformational medical technology to shape the world we want to live in and make that world possible by shortening the path from innovation to safety to access.

Read More

HEALTH TECHNOLOGY

Vicarious Surgical Announces Center of Excellence Agreements with HCA Healthcare and UH Ventures to Advance System Design

Vicarious Surgical Inc. | July 08, 2022

Vicarious Surgical Inc. a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it has signed collaborative Center of Excellence agreements with both HCA Healthcare, one of the nation’s leading providers of healthcare services comprising 182 hospitals, and University Hospitals Ventures, the innovation and commercialization arm of University Hospitals (UH), a comprehensive health system with more than 20 hospitals, over 50 health centers, and over 200 physician offices in northern Ohio. As part of these agreements, HCA Healthcare and UH Ventures will each provide user input through their system physicians as the Company advances the design of its Vicarious Surgical Robot. Through these distinct collaborations, Vicarious Surgical will gain unique exposure to the detailed surgical workflows at each of these partners and incorporate direct surgeon and administrator feedback into its total product ecosystem to meet the needs of major US hospital systems. Additionally, clinical and human-centered design experts from both HCA Healthcare and UH will assist Vicarious Surgical to further enhance product design, helping ensure readiness for streamlined adoption upon FDA Approval. “Establishing our Center of Excellence model with two leading U.S. health systems offers significant validation of our system’s in-hospital potential and creates an incredible opportunity to integrate real-world surgeon experiences and feedback as we work toward our system’s finalization. These partnerships establish two powerful innovation conduits through which our team gains unprecedented access to understanding and addressing the complexities of surgical workflow and hospital integration while building commercial expertise. Meanwhile, our clinical partners – HCA Healthcare and University Hospitals – become the first health systems to access our minimally invasive surgical robot and directly influence its advancement. We could not be more excited to partner with two of the top institutions in the country as we progress on our path to improve surgery for patients, surgeons, hospitals, and payors.” Adam Sachs, CEO and co-founder of Vicarious Surgical “Our surgical and innovation teams are on the cutting edge of new care technologies designed to benefit patients,” said Dr. Joseph Sabik, Chairman, Department of Surgery at University Hospitals. “Collaborating with Vicarious Surgical on their Center of Excellence model for training and next generation surgical robotics provides our team a thrilling front row seat in the quest to improve the landscape for minimally-invasive surgery that enhances patient care and clinical outcomes.” “University Hospitals’ goal is to be the most trusted health care partner in Northeast Ohio,” explained Kendra Gardiner, Director of Product Strategy for UH Ventures. “As part of this strategy, UH is dedicated to accelerating discovery, innovation and translation of scientific breakthroughs that address unmet clinical and social needs to enhance the lives of our patients, our communities and the world. We also aim to be the partner of choice by creating and sharing value together. This new relationship with Vicarious Surgical is one example of how we are advancing this objective.” About Vicarious Surgical Founded in 2014, Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goals of increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. About HCA Healthcare Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 182 hospitals and approximately 2,300 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom. HCA Healthcare subsidiary Health Insight Capital makes equity investments in early-stage companies that are selected to provide innovative solutions for use in health system operations and is an investor in Vicarious Surgical. Please click here to connect with HCA Healthcare on social media. About UH Ventures UH Ventures is the innovation and commercialization arm of University Hospitals (UH), a comprehensive health system with annual revenues in excess of $5.0 billion, more than 20 hospitals, more than 50 health centers and outpatient facilities, and over 200 physician offices located throughout 16 counties. UH’s goal is to be the most trusted health care partner in Northeast Ohio and UH Ventures furthers this objective by shaping new products, services, experiences, and companies that improve the lives of patients and caregivers. To advance the UH mission, UH Ventures strives to support a diverse portfolio of value-adding opportunities in health care, enhance the distinct and unique capabilities of the system, and foster a culture of discovery, innovation, and entrepreneurship within UH and the larger community. For caregivers, UH Ventures provides the tools and resources needed to nurture, validate, and advance ideas sparked by day-to-day insights. For potential partners, UH Ventures seeks to be a dynamic living laboratory where both clinical and product insights can help accelerate emerging technologies tackling health care’s most pressing problems.

Read More

HEALTH TECHNOLOGY

Netsmart Announces Intent to Become a Qualified Health Information Network to Drive the Evolution of Interoperability

Netsmart | September 23, 2022

Netsmart, the developer of the industry-leading CareFabric® platform for human services, post-acute care providers and payers announced its intent to apply to join the Trusted Exchange Framework and Common Agreement to become a Qualified Health Information Network. By supporting TEFCA, Netsmart continues its decade-long advancement of interoperability strategies to facilitate an open exchange of longitudinal healthcare data that will benefit individuals receiving care across the healthcare ecosystem. Once accepted as a QHIN, Netsmart will be part of a first-of-a-kind national data sharing network that will determine new standards for both private and public sectors. The Office of the National Coordinator for Health Information Technology is leading the charge and will oversee the QHIN process through the designation of The Sequoia Project as the recognized coordinating entity. Netsmart has been collaborating with the ONC and The Sequoia Project to help develop and provide feedback on the principles and procedures put forth by TEFCA. Netsmart is a longtime leader and advocate for open networks and interoperability standards to prioritize the needs of providers, clinicians, patients, and their families. This open network approach is in contrast to technology vendors who in some cases have sought to carve out proprietary networks that stifle the future of care coordination. The open and secure sharing of data is required to achieve effective care coordination that Netsmart supports as a founding member of the Carequality interoperability framework. The Netsmart network, CareConnect™, was built to offer clients seamless integration of health data and one point of access to the larger health data ecosystem. With the CareConnect solution, Netsmart was one of the first healthcare IT vendors to utilize the new 360X closed-loop referral standards in a production environment to bring to life true interoperability to minimize manual data entry which streamlines transitions of care and care coordination and reduces medication errors. By empowering providers to digitize their enterprise, Netsmart clients are projected to perform more than 3 billion secure health data exchanges facilitated through CareConnect in 2022. “It has always been our objective as a healthcare technology partner to offer comprehensive solutions and services that allow providers to remain competitive in a landscape that requires coordinated care and value-based practices for success. Becoming a Qualified Health Information Network aligns with our established history of being at the forefront of driving interoperability. As we take the next step in the evolution of data exchange, we look forward to collaborating with other healthcare IT vendors applying to participate as a QHIN to expand access to open networks for consumers nationwide.” Netsmart CEO Mike Valentine About Netsmart Netsmart, a leading provider of Software as a Service technology and services solutions, designs, builds and delivers electronic health records, health information exchanges, analytics and telehealth solutions and services that are powerful, intuitive and easy-to-use. Our platform provides accurate, up-to-date information that is easily accessible to care team members in the human services and post-acute care (which is comprised of home care and hospice and senior living) and payer markets. We make the complex simple and personalized so our clients can concentrate on what they do best: provide services and treatment that support whole-person care. By leveraging the powerful Netsmart network, care providers can seamlessly and securely integrate information across communities, collaborate on the most effective treatments and improve outcomes for those in their care. Our streamlined systems and personalized workflows put relevant information at the fingertips of users when and where they need it.

Read More